Home > Gastroenterology > ECCO 2020 > Gut Microbiome as Treatment Target > Response to faecal microbiota transplantation in UC

Response to faecal microbiota transplantation in UC

Presented By
Dr M. Quraishi, University Hospital Birmingham, UK; Dr L. Gogokhia, Weill Cornell Medicine, New York, USA
Conference
ECCO 2020
Trial
STOP-Colitis
In a substudy of STOP-Colitis, response to faecal microbiota transplantation (FMT) in ulcerative colitis (UC) patients was associated with a significant increase in mucosal gut-homing Treg cells and butyrate metabolism, along with a reduction in Th17 cells and multiple anti-microbial and pro-inflammatory pathways [1]. STOP-Colitis was a prospective, open-label pilot study of FMT in UC. In a substudy, changes in host colonic mucosal immune cell subsets and gene expression following FMT were explored. Participants received 8 FMT infusions over 8 weeks; of 17 patients, 12 completed 8 weeks of FMT per protocol. Response, defined by a reduction in Mayo score, was seen in 8 of 12 patients (67%). As first author Dr Mohammed Quraishi (University Hospital Birmingham, UK) explained, FMT responders showed a significant increase in Treg cells (Δ 5.02%; P<0.01), especially in effector-memory Treg cells (Δ 12%; P<0.001) and gut-homing Treg cells (Δ 18.55%; ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on